Targeting CDK4 and CDK6 kinases in breast cancer development
靶向乳腺癌发展中的 CDK4 和 CDK6 激酶
基本信息
- 批准号:10261468
- 负责人:
- 金额:$ 35.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-11 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAllograftingAntibodiesApoptosisBlocking AntibodiesBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Cancer TreatmentBreast Cancer cell lineBreast Cancer therapyCDK4 geneCancer ModelCell AgingCell CycleCell DeathCell ProliferationClinical TrialsCollaborationsComplexComplex AnalysisCultured CellsCyclin D1Cyclin-Dependent Kinase InhibitorCyclin-Dependent Kinase Inhibitor 2ACyclin-Dependent KinasesCyclinsCytostaticsDevelopmentEnrollmentEstrogen TherapyEstrogen receptor positiveGoalsHumanIn VitroInter-tumoral heterogeneityLaboratoriesLigandsMammary NeoplasmsMeasuresMusNatureOutcomePatient-derived xenograft models of breast cancerPatientsPentosephosphate PathwayPhosphotransferasesPlayProtein IsoformsProteinsReactive Oxygen SpeciesRefractoryRetinoblastoma ProteinRoleSurvival RateTestingUnited States Food and Drug AdministrationUp-RegulationWorkXenograft procedureanti-CTLA4anti-PD-1anti-canceranti-tumor immune responsebasecancer cellcancer typecheckpoint therapycombinatorialcyclin D3cytotoxicefficacy testingimmune checkpointimprovedin vivoinhibitor/antagonistmalignant breast neoplasmneoplastic cellnovelnovel therapeuticspatient derived xenograft modelpatient subsetsprogrammed cell death ligand 1programmed cell death protein 1responsetumortumor heterogeneitytumor metabolism
项目摘要
Project Summary/Abstract
This translational proposal focuses on the use of inhibitors of cyclin-dependent kinases CDK4 and CDK6 for
breast cancer treatment. CDK4 and CDK6 are components of the core cell cycle machinery that are activated
upon interaction with their regulatory subunits, the D-type cyclins (cyclins D1, D2 and D3). Inhibitors of
CDK4/6 palbociclib, ribociclib and abemaciclib received ‘Breakthrough Therapy’ designation status from the
FDA and have been approved for treatment of estrogen receptor-positive breast cancers. In addition, these
compounds are now in clinical trials for several other cancer types. A large number of studies demonstrated
that treatment of human cancer cells with CDK4/6 inhibitors blocks tumor cell proliferation, and in some cases
causes tumor cell senescence. Working together with Dr. Polyak, we observed that tumor cells expressing
high levels of cyclin D3-CDK6 complexes undergo cell death upon CDK4/6 inhibition. We found that cyclin D3-
CDK6, but not several other types of cyclin D-CDK4/6 complexes analyzed by us (such as cyclin D1-CDK4),
plays a rate-limiting role in regulating tumor cell metabolism, and protects tumor cells against elevated levels of
reactive oxygen species. In an independent study, we found that in mouse and human tumor cells, cyclin D-
CDK4 kinase regulates the levels of an immune checkpoint protein, programmed death-ligand 1 (PD-L1).
Using mouse cancer models and in vitro cultured cells, we found that treatment with CDK4/6 inhibitors results
in upregulation of PD-L1 protein levels in tumor cells. We also found that combined administration of CDK4/6
inhibitors with antibodies that target the interaction between programmed cell death protein 1 (PD-1) and its
ligand PD-L1 increased the efficacy of immune checkpoint therapy. In the studies proposed here, we will
extend these observations to breast cancers. In Aim 1, we will work with Drs. Polyak and Brown to test our
hypothesis that measuring cyclin D3 and CDK6 levels in human breast cancers may allow one to identify
breast cancer cases that are particularly sensitive to CDK4/6 inhibitor treatment, as cyclin D3/CDK6-high
tumors might undergo tumor cell death and tumor regression upon CDK4/6 inhibition. We will also explore
ways to trigger apoptosis of breast cancers expressing predominantly cyclin D1 and CDK4. We will address
these issues using xenografts of human breast cancer cell lines and patient-derived breast cancer xenografts.
We will also work with Drs. Polyak and Brown to address the intra- and inter-tumoral heterogeneity of breast
cancers, which may influence the outcomes. In Aim 2, we test our hypothesis that CDK4/6 inhibitor treatment
would increase the efficacy of immune checkpoint therapy for breast cancers and result in tumor regression
and improved survival rates in mouse breast cancer models. We will study this using mice bearing breast
cancer allografts as well as autochthonous triple-negative breast tumors. The expected overall impact of this
proposal is that it will provide means to identify breast cancer cases that are particularly sensitive to anti-
CDK4/6 therapy, and establish novel, highly effective combinatorial treatments involving CDK4/6 inhibitors.
项目总结/摘要
该翻译建议集中于使用细胞周期蛋白依赖性激酶CDK 4和CDK 6的抑制剂,
乳腺癌的治疗CDK 4和CDK 6是被激活的核心细胞周期机制的组分,
在与它们的调节亚基D型细胞周期蛋白(细胞周期蛋白D1、D2和D3)相互作用时。的抑制剂
CDK 4/6 palbociclib、ribociclib和abemaciclib获得了“突破性治疗”的认定资格。
FDA已批准用于治疗雌激素受体阳性乳腺癌。另外这些
化合物目前正在对其他几种癌症进行临床试验。大量研究表明,
用CDK 4/6抑制剂治疗人类癌细胞可以阻断肿瘤细胞增殖,在某些情况下,
导致肿瘤细胞衰老。与Polyak博士合作,我们观察到表达
高水平的细胞周期蛋白D3-CDK 6复合物在CDK 4/6抑制时经历细胞死亡。我们发现细胞周期蛋白D3-
CDK 6,而不是我们分析的其他几种类型的细胞周期蛋白D-CDK 4/6复合物(如细胞周期蛋白D1-CDK 4),
在调节肿瘤细胞代谢中起限速作用,并保护肿瘤细胞免受高水平的
活性氧物质。在一项独立的研究中,我们发现在小鼠和人类肿瘤细胞中,细胞周期蛋白D-
CDK 4激酶调节免疫检查点蛋白,程序性死亡配体1(PD-L1)的水平。
使用小鼠癌症模型和体外培养的细胞,我们发现用CDK 4/6抑制剂治疗导致
肿瘤细胞中PD-L1蛋白水平的上调。我们还发现,CDK 4/6联合给药
具有靶向程序性细胞死亡蛋白1(PD-1)及其受体之间相互作用的抗体的抑制剂,
配体PD-L1增加了免疫检查点疗法的功效。在本研究中,我们将
将这些观察结果扩展到乳腺癌。在目标1中,我们将与Polyak博士和Brown博士合作,
假设测量人类乳腺癌中细胞周期蛋白D3和CDK 6水平可以帮助人们识别
对CDK 4/6抑制剂治疗特别敏感的乳腺癌病例,如细胞周期蛋白D3/CDK 6高
在CDK 4/6抑制后,肿瘤可能经历肿瘤细胞死亡和肿瘤消退。我们还将探索
触发主要表达细胞周期蛋白D1和CDK 4的乳腺癌细胞凋亡的方法。我们将解决
这些问题使用人乳腺癌细胞系的异种移植物和患者来源的乳腺癌异种移植物。
我们还将与Polyak和Brown博士合作,解决乳腺癌的肿瘤内和肿瘤间异质性,
癌症,这可能会影响结果。在目标2中,我们检验了我们的假设,CDK 4/6抑制剂治疗
将增加乳腺癌免疫检查点疗法的疗效,并导致肿瘤消退
并提高了小鼠乳腺癌模型的存活率。我们将使用小鼠进行研究,
癌症同种异体移植物以及自体三阴性乳腺肿瘤。预期的整体影响
这项提案将提供一种方法来确定对抗-
CDK 4/6治疗,并建立新的,高效的组合治疗涉及CDK 4/6抑制剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter Sicinski其他文献
Peter Sicinski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter Sicinski', 18)}}的其他基金
Cyclin C-CDK8/19 kinases in development and in cancer
发育和癌症中的细胞周期蛋白 C-CDK8/19 激酶
- 批准号:
10579308 - 财政年份:2022
- 资助金额:
$ 35.19万 - 项目类别:
Cyclin C-CDK8/19 kinases in development and in cancer
发育和癌症中的细胞周期蛋白 C-CDK8/19 激酶
- 批准号:
10415467 - 财政年份:2022
- 资助金额:
$ 35.19万 - 项目类别:
Targeting CDK4 and CDK6 kinases in breast cancer development
靶向乳腺癌发展中的 CDK4 和 CDK6 激酶
- 批准号:
10627976 - 财政年份:2020
- 资助金额:
$ 35.19万 - 项目类别:
Targeting CDK4 and CDK6 kinases in breast cancer development
靶向乳腺癌发展中的 CDK4 和 CDK6 激酶
- 批准号:
10434105 - 财政年份:2020
- 资助金额:
$ 35.19万 - 项目类别:
Targeting CDK4 and CDK6 kinases in breast cancer development
靶向乳腺癌发展中的 CDK4 和 CDK6 激酶
- 批准号:
10023399 - 财政年份:2020
- 资助金额:
$ 35.19万 - 项目类别:
CDC7 kinase in normal and cancer cells: potential implications for cancer treatment
正常细胞和癌细胞中的 CDC7 激酶:对癌症治疗的潜在影响
- 批准号:
10063864 - 财政年份:2019
- 资助金额:
$ 35.19万 - 项目类别:
CDC7 kinase in normal and cancer cells: potential implications for cancer treatment
正常细胞和癌细胞中的 CDC7 激酶:对癌症治疗的潜在影响
- 批准号:
10526420 - 财政年份:2019
- 资助金额:
$ 35.19万 - 项目类别:
CDC7 kinase in normal and cancer cells: potential implications for cancer treatment
正常细胞和癌细胞中的 CDC7 激酶:对癌症治疗的潜在影响
- 批准号:
9916522 - 财政年份:2019
- 资助金额:
$ 35.19万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 35.19万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 35.19万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 35.19万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 35.19万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 35.19万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 35.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 35.19万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 35.19万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 35.19万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 35.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists